Treatment Sequencing in CLL

CME

Optimal Therapeutic Sequencing in Relapsed/Refractory CLL: A Global Perspective

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 28, 2024

Expiration: June 29, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Currently, how confident are you in your ability to plan optimal therapeutic strategies for patients with R/R CLL based on current guidelines, available clinical evidence, and expert recommendations?

2.

A 72-year-old man with CLL (unmutated IGHV, del(11q), and no TP53 mutation or del(17p)) was treated with venetoclax plus obinutuzumab; he tolerated treatment well and completed 12-month therapy, but after 3 years, showed progressive disease with lymphocytosis, lymphadenopathy, and anemia. He was treated with acalabrutinib, which he tolerated well, but 2 years later, he has slowly progressive symptomatic disease. His WBC count is 42 x 109/L, Hgb is 10.8 g/dL, and platelet count is 90 x 109/L. FISH shows del(11q) and no del(17p) or TP53 mutation; however, mutation testing reveals a BTK C481 mutation.

In your current practice, what would you recommend for this patient?